The United Kingdom and the United States have announced a important bilateral deal that will preserve zero duties on UK medicine exports entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the National Health Service (NHS). This move guarantees that import taxes on these vital products will be held at nothing for a period of 36 months.
This development follows earlier statements to hike import taxes on patented drug products, with potential rates discussed reaching 100%.
"This deal between the UK reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Impact
Drugs are one of the Britain's biggest goods shipped to the US, which is by far the largest destination for large UK drugmakers.
Statistics indicate that in the 12 months leading up to September, the UK exported pharmaceutical products totaling £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This deal safeguards employment, increases investment and facilitates the UK to emerge as a global hub for life sciences," a minister commented.
Detailed British Pledges
The agreement involves several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to raise total health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments were more than 20%.
Recent Tensions
The deal comes amid a ongoing dispute between the drug companies and the British authorities over spending levels and regulatory access.
These tensions were exacerbated by claims that US customers were charged significantly more for the identical medicines than patients in the Britain and the EU.
Recently, several large drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a share of its resources over the past decade.